Summary of COVID-19 medicines guidance: Policy, Commissioning and Managerial

This page summarises and signposts to medicine related guidance we’re aware of from professional and government bodies relating to Policy and Commissioning during coronavirus pandemic.

This page has been put together rapidly in relation to the COVID-19 pandemic.

Whilst we have tried to ensure that the information on this page is complete, please report a concern if you feel anything is omitted or inaccurate.

To see our professional guidance summaries for other clinical areas, click here

Advice in this area includes:

NHS England/NHS Improvement: Interim Clinical Commissioning Policy: Remdesivir for patients hospitalised with COVID-19 (adults and children 12 years and over) 

Last updated 7 July 2020

  • This policy sets out the interim clinical commissioning position for the use of remdesivir for patients with COVID-19.

 

NHS England/NHS Improvement: Clinical management of persons admitted to hospital with suspected COVID-19 infection

Last updated 19 March 2020

  • This generalised guidance is for clinicians caring for adults and children admitted to hospital with suspected COVID-19 infection.
  • It describes the categorisation of types of clinical syndromes associated with COVID-19 infection
  • Early supportive therapy and monitoring including the need for oxygen supplementation, the use of empirical antibiotic treatment, use of corticosteroids and use of non-invasive ventilation is discussed.
  • Management of hypoxaemic respiratory failure, Acute Respiratory Distress Syndrome (ARDS), and septic shock is included.
  • General Guidance is also given on the management of pregnant patients.

 

NHS England/NHS Improvement: Clinical guide for the management of non-coronavirus patients requiring acute treatment: general and internal medicine during the coronavirus pandemic

Last updated 20 March 2020

  • General guidance is included on reprioritisation of inpatients, outpatients, diagnostic procedures and elective work, in order to release clinicians to support emergency care. Guidance on leadership and communication is also given.

 

NHS England/NHS Improvement: Clinical guide for the management of remote consultations and remote working in secondary care during the coronavirus pandemic

Last updated 27 March 2020

  • This guidance for clinicians and managers outlines practical information about delivering remote consultations and other ways of remote working in secondary care
  • It includes detailed guidance on how to conduct the consultation itself, and exception criteria.

 

HM Government: COVID-19: guidance for health professionals

Last updated 23 July 2020

  • This is a repository of a number of guidelines regarding the assessment and management of suspected and confirmed UK cases.
  • It includes general guidance as well as guidance on infection prevention and control, adult social care, sampling and laboratory diagnostics, and surveillance reports.

 

HM Government: Guidance on shielding and protecting people who are clinically extremely vulnerable from COVID-19

Last updated 14 July 2020

  • This guidance defines those people who are classed as clinically extremely vulnerable.
  • It is written for these patient groups, their family, friends and carers.
  • It provides a definition of shielding and other ways to minimise risk, and
  • It includes the most recent stepped down guidance including the changes which came into effect as of the 6th July and that shielding will be paused from 1st August.
  • A link to the local lockdown guidance is also included.

 

HM Government: Medicines and Healthcare products Regulatory Agency (MHRA) Coronavirus Yellow Card reporting site 

Summary

  • Healthcare professionals, patients and carers can report all suspected adverse drug reactions associated with any medicines used in patients with confirmed or suspected COVID-19.
  • This includes medicines to manage long term or pre-existing conditions and medicines being used off-label and in clinical trials.
  • The site has been developed as part of the MHRA’s work to protect the public through enhanced COVID-19 vigilance and in preparation for large-scale use of potential new or repurposed medicines, medical devices, diagnostic tests and future vaccines.
  • Reporting for incidents in clinical trials should also still be reported in line with trial protocols.

 

Administration update  (27 July 2020): new resources added to the page and administrative amendments made as indicated by red text.